The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT06059664

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06059664
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06059664. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-23 (actual); primary completion 2027-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
Condition
Kidney Transplant; Complications
Intervention (Drug)
Finerenone Oral Tablet
Intervention (Drug)
Placebo
Lead sponsor
University of North Carolina, Chapel Hill (class: other)
Collaborator
Bayer (class: industry)
Collaborator
Weill Medical College of Cornell University (class: other)
Collaborator
University of Cincinnati (class: other)

Record details

Record id
cardio:ct-nct06059664
Content hash
4f39e19420ca2991b37853f4969cfa89bf51f0fe1ff7a13d5e255a3d3194f988